A Phase I/II Study of Intratumoral Injection of SD-101
Status:
Completed
Trial end date:
2017-01-26
Target enrollment:
Participant gender:
Summary
This phase 1-2 trial studies the side effects and best dose of ipilimumab in combination with
toll-like receptor 9 (TLR9) agonist SD-101 and radiation therapy in treating patients with
recurrent low-grade B-cell lymphoma.